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ABSTRACT: Introduction: Scleroderma encompasses a broad 
spectrum of clinical manifestations, being subdivided into 
localized and systemic forms. The localized form exclusively 
affects the skin and surrounding tissues and has a partially 
known physiopathology and epidemiology, with the majority 
of epidemiological studies focusing on the systemic form and 
extrapolating its results to the other one. This study aim to clarify 
the epidemiology of localized scleroderma in the state of Ceará, 
Brazil, in order to understand its risk factors in the Brazilian 
population. This is the first Brazilian epidemiological study of 
localized scleroderma. Methods: A quantitative retrospective 
study was conducted, in which all the records of the medical 
consultations performed at the Reference Center for Dermatology 
Dona Libânia (CDERM), Fortaleza, Ceará, Brazil, in 2015 were 
analysed using the variables: name, gender, date of consultation, 
medical record number, presumptive or confirmed diagnosis and 
the patient’s frequency in CDERM. Results: Of the 19.576 patients 
analysed, 124 were diagnosed with scleroderma, representing 
an approximate incidence of 0.62% in the service. Among 
these patients, 96 (77.42%) were female and 28 (22.58%) were 
male. The mean age of the patients was 29.7 years. Discussion: 
Prevalence and distribution by sex obeyed the worldwide trends 
reported in other studies. However, there was a higher prevalence 
of diagnoses in females in the pediatric age group, which contrasts 
with data in the literature affirming that differences in gender 
distribution only begin in early adolescence. This difference may 
be due to cultural factors, underdiagnosis in the male population 
or a regional trend in the Brazilian epidemiology of localized 
scleroderma. Conclusion: More extensive and multicentric studies 
are needed to better understand the disease in our population and, 
thus, serve as a basis for healthcare in the future.
Keywords: Scleroderma, localized; Epidemiology; Dermatology; 
Rheumatology.
RESUMO: Introdução: A esclerodermia abrange amplo espectro 
de manifestações clínicas, sendo subdividida em forma localizada 
e sistêmica. A forma localizada, com acometimento exclusivamente 
cutâneo e de tecidos circunvizinhos, apresenta fisiopatologia e 
epidemiologia parcialmente conhecidas pela comunidade científica, 
com a maioria dos estudos epidemiológicos se concentrando na 
forma generalizada e extrapolando seus resultados para a outra 
forma. Este estudo tem o intuito de esclarecer a epidemiologia da 
esclerodermia localizada no estado do Ceará, visando compreender 
seus fatores de risco na população brasileira. Trata-se do primeiro 
estudo epidemiológico brasileiro acerca da esclerodermia localizada. 
Metodologia: Delineou-se um estudo retrospectivo quantitativo, 
no qual foram analisados todos os registros das consultas médicas 
realizadas no Centro de Referência em Dermatologia Dona Libânia 
(CDERM), Fortaleza, Ceará, em 2015, através das variáveis: nome, 
sexo, idade, data da consulta, número do prontuário, diagnóstico 
presuntivo ou confirmado e a frequência do paciente no CDERM. 
Resultados: Dos 19.576 pacientes analisados, 124 pacientes foram 
diagnosticados com esclerodermia localizada, representando uma 
incidência aproximada de 0,62% no serviço. Dentre estes pacientes, 96 
(77,42%) eram do sexo feminino e 28 (22,58%) do sexo masculino. A 
idade média dos pacientes foi de 29,7 anos. Discussão: A prevalência 
e distribuição por sexo obedeceram às tendências mundiais relatadas 
em outros trabalhos. Entretanto, constatou-se elevada prevalência 
de diagnóstico no sexo feminino na faixa etária pediátrica, o que 
contrasta com dados na literatura que afirmam que as diferenças na 
distribuição de gênero começam a existir no início da adolescência. 
Esta diferença pode dever-se à fatores culturais, subdiagnóstico na 
população masculina ou uma tendência regional na epidemiologia 
da esclerodermia localizada. Conclusão: Este estudo corresponde ao 
primeiro estudo epidemiológico brasileiro acerca da esclerodermia 
localizada, sendo necessários estudos mais amplos e multicêntricos 
que permitam entender melhor a doença na nossa população e, assim, 
possam servir de base para futuras ações assistenciais
Palavras-chave: Esclerodermia localizada; Epidemiologia; 
Dermatologia; Reumatologia.
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INTRODUCTION
Scleroderma is a rare multisystemic disease, with morphological and functional impairment of 
small blood vessels, fibrosis of the skin and internal organs, 
activation of the immune system, and autoimmunity1. 
The term scleroderma comprises various clinical entities, 
encompassing both localized and systemic forms. The 
localized form, also known as morphea, is restricted to skin 
and subcutaneous involvement, and may extend to bones 
and adjacent neurological structures. The systemic form 
is subdivided into limited and diffuse, and is characterized 
by involvement of internal organs, notably gastrointestinal 
tract, lung, and kidneys, in addition to skin involvement2. 
Due to the scope of the term, the literature on scleroderma 
encounters difficulties in relation to the standardization 
of its terminology, notably in the term generalized 
scleroderma. In this article, generalized scleroderma refers 
to a variant of localized scleroderma.
Localized scleroderma has a wide spectrum of 
manifestations, ranging from small plaques to large 
aesthetic and functional deformities. Among the variants, 
the following can be mentioned: circumscribed, linear, 
generalized, pansclerotic, and mixed form³. The initial 
lesion is characterized by erythema, progressing to a 
yellow-white plaque limited by blue-violet erythema. As 
skin infiltration occurs, atrophy of hair follicles and hyper- 
or hypopigmentation are observed4.
The circumscribed variant, also called plaque 
scleroderma, preferentially affects the trunk and manifests 
itself as indurated, infiltrated, circumscribed plaques, with 
undefined borders, with a violet ring and absence of hair, 
as well as anhidrosis. In the linear subtype, there are linear 
bands of sclerosis that can advance to subcutaneous, muscle, 
and bone tissue, generating deformities. The generalized 
variant has four or more confluent sclerotic plaques larger 
than 3 cm. It differs from systemic forms in that it does 
not present Raynaud’s phenomenon or capillaroscopic 
changes. The pansclerotic subtype leads to generalized 
and full-thickness skin involvement. The mixed form has 
manifestations of two or more of the variants described6.
The etiology and pathogenesis of localized 
scleroderma are still unknown, probably involving exposure 
to environmental factors in genetically predisposed 
individuals. No specific genetic changes were found in 
this form of scleroderma, although associations with other 
autoimmune diseases have been described5,6. In contrast, 
different gene loci have already been associated with 
systemic scleroderma, including changes in the HLA, 
IRF5, CD247, BANK1, STAT4, TNFSF4, and BLK6 genes. 
Multiple environmental factors seem to be involved, such as 
radiation exposure, trauma, medications, Lyme disease, and 
viral infections5. Despite having similar pathophysiological 
aspects, localized scleroderma differs significantly from 
its systemic form, with only nine cases described in the 
literature of patients with localized scleroderma that 
progressed to systemic sclerosis7.
Few studies have been conducted on the 
epidemiology of localized scleroderma, with a prevalence 
ranging from 0.4 to 2.7 per 100,000 people2,8,9. The female 
sex is predominantly affected, and the peak incidence 
according to age depends on the clinical variant. In plaque 
scleroderma, the most common form, the mean age of 
presentation is in the fourth decade of life, while the linear 
and pansclerotic variants predominate in the pediatric 
age group10. The generalized variant, in turn, is typical of 
adults4.
Brazilian epidemiological data on localized 
scleroderma are scarce and most of them are restricted 
to systemic forms, making a detailed analysis of the risk 
factors related to the localized form in Brazil difficult. In 
our research, we did not find any epidemiological study 
carried out in Brazil regarding localized scleroderma. 
Thus, the relevance of an epidemiological study focusing 
on this form of scleroderma is justified, to clarify aspects 
related to the prevalence, risk factors, and pathogenesis of 
localized scleroderma.
METHODS
We carried out a retrospective quantitative study, 
in which all records of medical consultations held at Dona 
Libânia Dermatology Center (CDERM), Fortaleza, Ceará, 
from January to December 2015, were analyzed.
The handwritten records provided the following 
variables: name, sex, age, date of consultation, medical 
record number, presumptive or confirmed diagnosis, 
and patient’s frequency at CDERM (first or follow-up 
consultation). Based on the variable name, 19,593 patients 
were treated in the stipulated period, excluding patients 
treated by non-medical health professionals. Of these, 17 
patients whose identification was impaired by poor quality 
handwritten records were excluded. The number of follow-
up consultations at CDERM was counted.
Of these 19,576 records, those whose diagnosis 
was localized scleroderma were selected, in order to know 
its incidence in this service and to analyze its variables in 
search of causal relationships. Patients with systemic forms 
of scleroderma were excluded.
Due to technical-operational limitations regarding 
patients with few consultations at the CDERM at the time 
of the research, with handwritten medical records available 
only to patients with multiple follow-up consultations, 
data related to the therapy used in the treatment of the 
selected patients were not available for most of the 
patients analyzed, as well as data related to the localized 
scleroderma subtype.
Data were collected from October 2016 to June 
2017. The variables were entered into a Microsoft Office 
Excel ® spreadsheet, where they were subjected to 
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statistical analysis of absolute and relative frequencies.
With regard to the Introduction and Discussion, 
MedLine® and Google Scholar® databases were searched 
using the search terms “localized scleroderma”, “morphea”, 
“epidemiology”, and “Brazil”. Search terms and related 
articles were searched in English and Portuguese. Articles 
on systemic scleroderma were excluded. Thirteen articles 
published between 1993 and 2019 were selected. No 
articles were found on the epidemiology of localized 
scleroderma in Brazil in both databases.
The research project was sent to and approved by 
the CDERM Ethics Committee, according to the ethical 
dictates of respect for patient confidentiality and autonomy. 
There is no conflict of interest in this work.
RESULTS
Of the 19,576 patients analyzed, 124 patients were 
diagnosed with localized scleroderma, representing an 
approximate incidence of 0.62% at the service. Of these 
patients, 96 (77.42%) were female and 28 (22.58%) were 
male. The mean age of the patients was 29.7 years. The 
detailed age is shown in Table 1.
Table 1. Age and sex of patients with localized scleroderma
Age Absolute number % Male Female
0-10 14 11.29% 2 12
11-20 33 26.61% 11 22
21-30 24 19.36% 5 19
31-40 22 17.74% 4 18
41-50 13 10.48% 3 10
51-60 11 8.87% 2 9
61-70 4 3.23% 0 4
>70 3 2.42% 1 2
The recurrence to the service varied, as can be seen 
in Table 2. A total of 299 consultations were carried out 
over the year with these patients. Most patients (62.1%) 
reconsulted at least once during the year. Of the 124 
patients, 22 (17.74%) had another dermatological condition 
besides localized scleroderma. Among other dermatological 
comorbidities, we can highlight vitiligo (present in 6 of the 
patients), leprosy (present in 2 of the patients), and acne 
(present in 2 of the patients).










Regarding the clinical subtypes, two patients were 
classified as having scleroderma en coup de sabre, one 
patient as having generalized scleroderma and the others 
as having localized scleroderma.
DISCUSSION
Localized scleroderma is a rare disease, with 
previous studies showing a prevalence between 0.4 
and 2.7 per 100,000 inhabitants². Based on data from 
the Brazilian Institute of Geography and Statistics 
(IBGE) regarding the population of Ceará in 2015, and 
assuming that a considerable majority of patients with 
localized scleroderma, or even approximately 100%, were 
referred to the center studied, as it is the most important 
dermatology center in Ceará, an estimated prevalence of 
1.39 per 100,000 inhabitants was found in our population, 
in accordance with that described in the literature of 
other countries. This prevalence may be underestimated, 
considering the possible underdiagnosis of this condition 
- the mean time between the onset of symptoms and the 
diagnosis of juvenile localized scleroderma, for example, 
is 11 to 13 months11. A study carried out with 750 children 
with localized scleroderma revealed that in about 20% there 
was a delay of more than 2 years to reach the diagnosis8, 
in addition to a minority of patients referred to smaller 
dermatology services.
The sex prevalence was also consistent with that 
found by other studies: the literature shows a female 
prevalence of 2.4 to 4.2: 1²,6. Our study showed a ratio 
of 3.4: 1, with women being the most affected sex in 
all age groups (Table 1). Interestingly, the age group 
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that showed the highest female prevalence was that of 
patients under the age of 10, with a ratio of 6: 1, being 
inconsistent with the data in the literature that female 
prevalence is more significant after 10 years of age8. As 
there are no comparative data in Ceará or in Brazil, it is 
not possible to determine whether this would be a regional 
trend or be correlated with other factors, such as a greater 
underdiagnosis of males in this age group due to a lower 
diagnostic suspicion, for example.
Regarding the age group of the population studied, 
our study showed a prevalence of the adult population 
in relation to the pediatric population of approximately 
1:6. Previous studies have shown a similar prevalence 
between the two populations². The study with the longest 
follow-up carried out to date, which evaluated the 
incidence of localized scleroderma over a 33-year period 
in Olmsted County, Minnesota, United States, considering 
all age groups, demonstrated that the incidence increased 
significantly after 33 years of age in the 82 patients analyzed 
between 1960 and 1993¹². Our study showed a mean age 
of 29.7 years. However, since this is a study of prevalence, 
not incidence, it is possible to hypothesize that the mean 
age of the initial diagnosis would be even lower, possibly 
demonstrating an earlier age of onset of the disease in the 
population studied in relation to the literature. An earlier 
age of onset of symptoms may have an implication in the 
prognosis: adult patients who started having symptoms 
earlier, in pediatric age, when they have active disease, 
tend to have less severe activity compared to those who 
started having symptoms later on13.
Association of localized scleroderma with other 
autoimmune diseases is already described in the literature. 
Concomitance with vitiligo has already been reported, but 
in most publications, in isolated cases. A study carried out 
with 245 patients with localized scleroderma showed that 
approximately 1.2% of them had vitiligo concomitantly6. 
In our study, the association was about 4 times greater, 
with 4.8% of patients having vitiligo. There was also a 
female predominance of 2:1. Association with Sjögren’s 
syndrome, also described in the literature, was found in 
one patient. Associations with other autoimmune diseases, 
such as systemic lupus erythematosus, rheumatoid arthritis, 
psoriasis, inflammatory bowel disease, and multiple 
sclerosis are also well established in the literature 6. 
However, they were not identified among the patients 
analyzed in this study.
CONCLUSIONS
Localized scleroderma is a rare disease whose 
pathogenesis is not yet completely clarified. There is a 
lack of studies on localized scleroderma in the Brazilian 
literature, thus making it more difficult to understand 
its prevalence, risk factors, and associations with other 
diseases. This is the first Brazilian epidemiological study 
on localized scleroderma, and there is a need for broader 
and multicenter studies that allow a better understanding of 
the disease in the Brazilian population and, thus, can serve 
as a basis for future care actions.
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